A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study
Summary Objective Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients with treatment‐resistant seizures who were taking one to three concomitant antiepileptic drugs (AEDs). The...
Gespeichert in:
| Veröffentlicht in: | Epilepsia (Copenhagen) 2015-12, Vol.56 (12), p.1921-1930 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1930 |
|---|---|
| container_issue | 12 |
| container_start_page | 1921 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 56 |
| creator | Runge, Uwe Arnold, Stephan Brandt, Christian Reinhardt, Fritjof Kühn, Frank Isensee, Kathleen Ramirez, Francisco Dedeken, Peter Lauterbach, Thomas Noack‐Rink, Matthias Mayer, Thomas |
| description | Summary
Objective
Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients with treatment‐resistant seizures who were taking one to three concomitant antiepileptic drugs (AEDs). The VITOBA study (NCT01098162) evaluated the effectiveness and tolerability of adjunctive lacosamide added to one baseline AED in real‐world clinical practice.
Methods
We conducted a 6‐month observational study at 112 sites across Germany. Adult patients (≥16 years) with POS received lacosamide adjunctive to only one baseline AED. Seizure frequency reduction at the end of the observation period was compared with a 3‐month retrospective baseline period.
Results
Five hundred seventy‐one patients received lacosamide at least once (Safety Set [SS]); 520 provided evaluable seizure records (Full Analysis Set [FAS]); and 499 took in‐label dosages of lacosamide (up to 400 mg) and were evaluated for effectiveness (modified FAS). Median baseline seizure frequency was 2.0 per 28 days: 47.1% of patients (235/499, mFAS) took a concomitant sodium channel–blocking (SCB) AED; 38.1% (190/499) had only one lifetime AED; and 18.4% (92/499) were aged ≥65 years (mFAS). At the final visit, 72.5% (358/494) of patients showed a ≥50% reduction in seizure frequency from baseline, 63.8% (315/494) showed a ≥75% reduction, and 45.5% (225/494) were seizure‐free. Seizure freedom rates were higher in patients aged ≥65 years (56.7%) compared with patients aged 5 years duration (41.0%), and when added to first monotherapy (60.5%) rather than as a later therapy option. Treatment‐emergent adverse events (TEAEs) were reported by 48.5% (277/571) of patients (SS), with a profile similar to that observed in pivotal trials; 466 of patients (81.6%, SS) continued lacosamide therapy after the trial.
Significance
These results suggest that lacosamide use, added to one concomitant AED, was effective at improving seizure control and was well tolerated in patients treated in routine clinical practice. |
| doi_str_mv | 10.1111/epi.13224 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4737283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1749613307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5134-f1c4aa9c0cc1a0bcaa1670aa01569c317d6c8015bd71479fb90cb13798c5d7463</originalsourceid><addsrcrecordid>eNp1ksFu1DAQhiMEokvhwAsgS1zgsK0dJ3HCodJSFVipUjksXKOJPem68trBdrYKJx6B1-I1eBLcplSAhC_WyN_883tmsuw5o0csnWMc9BHjeV48yBaszOslY5V4mC0oZXzZlDU9yJ6EcEUpFZXgj7ODvCrzqhFskf1YEeusthH9Hm3UzoIhIY5qIrgHM0LU9pLELRLse5RRJwpDIGAVCdBjnIjriQHpAuy0QgJKoSLRkZ2zLuV5GCaiLRmSUioQyLWOW5IcGxzCNEcD-KjB_Pz23dmAkQTUX0eP4SZPgTYTkUZbLZO1wUMyIfEN2SRPn9ebi7er2e_T7FEPJuCzu_sw-_TubHP6YXl-8X59ujpfypLxYtkzWQA0kkrJgHYSIPWKAlBWVo3kTKhK1inolGCFaPquobJjXDS1LJUoKn6Yncy6w9jtUMn0KQ-mHbzegZ9aB7r9-8XqbXvp9m0huMhrngRe3Ql492XEENudDhKNAYtuDC0TRVMxzqlI6Mt_0Cs3-jSiW6oum6YSLFGvZ0p6F4LH_t4Mo-3NgrSp3e3tgiT2xZ_u78nfG5GA4xm4ThOa_q_Unn1cz5K_AHoNy9s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1748599671</pqid></control><display><type>article</type><title>A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Runge, Uwe ; Arnold, Stephan ; Brandt, Christian ; Reinhardt, Fritjof ; Kühn, Frank ; Isensee, Kathleen ; Ramirez, Francisco ; Dedeken, Peter ; Lauterbach, Thomas ; Noack‐Rink, Matthias ; Mayer, Thomas</creator><creatorcontrib>Runge, Uwe ; Arnold, Stephan ; Brandt, Christian ; Reinhardt, Fritjof ; Kühn, Frank ; Isensee, Kathleen ; Ramirez, Francisco ; Dedeken, Peter ; Lauterbach, Thomas ; Noack‐Rink, Matthias ; Mayer, Thomas</creatorcontrib><description>Summary
Objective
Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients with treatment‐resistant seizures who were taking one to three concomitant antiepileptic drugs (AEDs). The VITOBA study (NCT01098162) evaluated the effectiveness and tolerability of adjunctive lacosamide added to one baseline AED in real‐world clinical practice.
Methods
We conducted a 6‐month observational study at 112 sites across Germany. Adult patients (≥16 years) with POS received lacosamide adjunctive to only one baseline AED. Seizure frequency reduction at the end of the observation period was compared with a 3‐month retrospective baseline period.
Results
Five hundred seventy‐one patients received lacosamide at least once (Safety Set [SS]); 520 provided evaluable seizure records (Full Analysis Set [FAS]); and 499 took in‐label dosages of lacosamide (up to 400 mg) and were evaluated for effectiveness (modified FAS). Median baseline seizure frequency was 2.0 per 28 days: 47.1% of patients (235/499, mFAS) took a concomitant sodium channel–blocking (SCB) AED; 38.1% (190/499) had only one lifetime AED; and 18.4% (92/499) were aged ≥65 years (mFAS). At the final visit, 72.5% (358/494) of patients showed a ≥50% reduction in seizure frequency from baseline, 63.8% (315/494) showed a ≥75% reduction, and 45.5% (225/494) were seizure‐free. Seizure freedom rates were higher in patients aged ≥65 years (56.7%) compared with patients aged <65 years (43.1%), in patients with ≤5 years epilepsy duration (52.5%) versus >5 years duration (41.0%), and when added to first monotherapy (60.5%) rather than as a later therapy option. Treatment‐emergent adverse events (TEAEs) were reported by 48.5% (277/571) of patients (SS), with a profile similar to that observed in pivotal trials; 466 of patients (81.6%, SS) continued lacosamide therapy after the trial.
Significance
These results suggest that lacosamide use, added to one concomitant AED, was effective at improving seizure control and was well tolerated in patients treated in routine clinical practice.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.13224</identifier><identifier>PMID: 26526971</identifier><identifier>CODEN: EPILAK</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetamides - administration & dosage ; Acetamides - adverse effects ; Acetamides - therapeutic use ; Adjunctive ; Adolescent ; Adult ; Age Factors ; Aged ; Anticonvulsants - administration & dosage ; Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; Antiepileptic drug ; Clinical medicine ; Drug Synergism ; Drug Therapy, Combination ; Epilepsies, Partial - drug therapy ; Epilepsy ; Female ; Full‐Length Original Research ; Humans ; Male ; Middle Aged ; Open‐label ; Prospective Studies ; Real‐world ; Safety ; Treatment ; Treatment Outcome ; Young Adult</subject><ispartof>Epilepsia (Copenhagen), 2015-12, Vol.56 (12), p.1921-1930</ispartof><rights>2015 The Authors. published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.</rights><rights>2015 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.</rights><rights>Copyright © 2015 International League Against Epilepsy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5134-f1c4aa9c0cc1a0bcaa1670aa01569c317d6c8015bd71479fb90cb13798c5d7463</citedby><cites>FETCH-LOGICAL-c5134-f1c4aa9c0cc1a0bcaa1670aa01569c317d6c8015bd71479fb90cb13798c5d7463</cites><orcidid>0000-0001-8666-1640</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.13224$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.13224$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26526971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Runge, Uwe</creatorcontrib><creatorcontrib>Arnold, Stephan</creatorcontrib><creatorcontrib>Brandt, Christian</creatorcontrib><creatorcontrib>Reinhardt, Fritjof</creatorcontrib><creatorcontrib>Kühn, Frank</creatorcontrib><creatorcontrib>Isensee, Kathleen</creatorcontrib><creatorcontrib>Ramirez, Francisco</creatorcontrib><creatorcontrib>Dedeken, Peter</creatorcontrib><creatorcontrib>Lauterbach, Thomas</creatorcontrib><creatorcontrib>Noack‐Rink, Matthias</creatorcontrib><creatorcontrib>Mayer, Thomas</creatorcontrib><title>A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Summary
Objective
Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients with treatment‐resistant seizures who were taking one to three concomitant antiepileptic drugs (AEDs). The VITOBA study (NCT01098162) evaluated the effectiveness and tolerability of adjunctive lacosamide added to one baseline AED in real‐world clinical practice.
Methods
We conducted a 6‐month observational study at 112 sites across Germany. Adult patients (≥16 years) with POS received lacosamide adjunctive to only one baseline AED. Seizure frequency reduction at the end of the observation period was compared with a 3‐month retrospective baseline period.
Results
Five hundred seventy‐one patients received lacosamide at least once (Safety Set [SS]); 520 provided evaluable seizure records (Full Analysis Set [FAS]); and 499 took in‐label dosages of lacosamide (up to 400 mg) and were evaluated for effectiveness (modified FAS). Median baseline seizure frequency was 2.0 per 28 days: 47.1% of patients (235/499, mFAS) took a concomitant sodium channel–blocking (SCB) AED; 38.1% (190/499) had only one lifetime AED; and 18.4% (92/499) were aged ≥65 years (mFAS). At the final visit, 72.5% (358/494) of patients showed a ≥50% reduction in seizure frequency from baseline, 63.8% (315/494) showed a ≥75% reduction, and 45.5% (225/494) were seizure‐free. Seizure freedom rates were higher in patients aged ≥65 years (56.7%) compared with patients aged <65 years (43.1%), in patients with ≤5 years epilepsy duration (52.5%) versus >5 years duration (41.0%), and when added to first monotherapy (60.5%) rather than as a later therapy option. Treatment‐emergent adverse events (TEAEs) were reported by 48.5% (277/571) of patients (SS), with a profile similar to that observed in pivotal trials; 466 of patients (81.6%, SS) continued lacosamide therapy after the trial.
Significance
These results suggest that lacosamide use, added to one concomitant AED, was effective at improving seizure control and was well tolerated in patients treated in routine clinical practice.</description><subject>Acetamides - administration & dosage</subject><subject>Acetamides - adverse effects</subject><subject>Acetamides - therapeutic use</subject><subject>Adjunctive</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Anticonvulsants - administration & dosage</subject><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antiepileptic drug</subject><subject>Clinical medicine</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Epilepsies, Partial - drug therapy</subject><subject>Epilepsy</subject><subject>Female</subject><subject>Full‐Length Original Research</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Open‐label</subject><subject>Prospective Studies</subject><subject>Real‐world</subject><subject>Safety</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1ksFu1DAQhiMEokvhwAsgS1zgsK0dJ3HCodJSFVipUjksXKOJPem68trBdrYKJx6B1-I1eBLcplSAhC_WyN_883tmsuw5o0csnWMc9BHjeV48yBaszOslY5V4mC0oZXzZlDU9yJ6EcEUpFZXgj7ODvCrzqhFskf1YEeusthH9Hm3UzoIhIY5qIrgHM0LU9pLELRLse5RRJwpDIGAVCdBjnIjriQHpAuy0QgJKoSLRkZ2zLuV5GCaiLRmSUioQyLWOW5IcGxzCNEcD-KjB_Pz23dmAkQTUX0eP4SZPgTYTkUZbLZO1wUMyIfEN2SRPn9ebi7er2e_T7FEPJuCzu_sw-_TubHP6YXl-8X59ujpfypLxYtkzWQA0kkrJgHYSIPWKAlBWVo3kTKhK1inolGCFaPquobJjXDS1LJUoKn6Yncy6w9jtUMn0KQ-mHbzegZ9aB7r9-8XqbXvp9m0huMhrngRe3Ql492XEENudDhKNAYtuDC0TRVMxzqlI6Mt_0Cs3-jSiW6oum6YSLFGvZ0p6F4LH_t4Mo-3NgrSp3e3tgiT2xZ_u78nfG5GA4xm4ThOa_q_Unn1cz5K_AHoNy9s</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Runge, Uwe</creator><creator>Arnold, Stephan</creator><creator>Brandt, Christian</creator><creator>Reinhardt, Fritjof</creator><creator>Kühn, Frank</creator><creator>Isensee, Kathleen</creator><creator>Ramirez, Francisco</creator><creator>Dedeken, Peter</creator><creator>Lauterbach, Thomas</creator><creator>Noack‐Rink, Matthias</creator><creator>Mayer, Thomas</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8666-1640</orcidid></search><sort><creationdate>201512</creationdate><title>A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study</title><author>Runge, Uwe ; Arnold, Stephan ; Brandt, Christian ; Reinhardt, Fritjof ; Kühn, Frank ; Isensee, Kathleen ; Ramirez, Francisco ; Dedeken, Peter ; Lauterbach, Thomas ; Noack‐Rink, Matthias ; Mayer, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5134-f1c4aa9c0cc1a0bcaa1670aa01569c317d6c8015bd71479fb90cb13798c5d7463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acetamides - administration & dosage</topic><topic>Acetamides - adverse effects</topic><topic>Acetamides - therapeutic use</topic><topic>Adjunctive</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Anticonvulsants - administration & dosage</topic><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antiepileptic drug</topic><topic>Clinical medicine</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Epilepsies, Partial - drug therapy</topic><topic>Epilepsy</topic><topic>Female</topic><topic>Full‐Length Original Research</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Open‐label</topic><topic>Prospective Studies</topic><topic>Real‐world</topic><topic>Safety</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Runge, Uwe</creatorcontrib><creatorcontrib>Arnold, Stephan</creatorcontrib><creatorcontrib>Brandt, Christian</creatorcontrib><creatorcontrib>Reinhardt, Fritjof</creatorcontrib><creatorcontrib>Kühn, Frank</creatorcontrib><creatorcontrib>Isensee, Kathleen</creatorcontrib><creatorcontrib>Ramirez, Francisco</creatorcontrib><creatorcontrib>Dedeken, Peter</creatorcontrib><creatorcontrib>Lauterbach, Thomas</creatorcontrib><creatorcontrib>Noack‐Rink, Matthias</creatorcontrib><creatorcontrib>Mayer, Thomas</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Runge, Uwe</au><au>Arnold, Stephan</au><au>Brandt, Christian</au><au>Reinhardt, Fritjof</au><au>Kühn, Frank</au><au>Isensee, Kathleen</au><au>Ramirez, Francisco</au><au>Dedeken, Peter</au><au>Lauterbach, Thomas</au><au>Noack‐Rink, Matthias</au><au>Mayer, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2015-12</date><risdate>2015</risdate><volume>56</volume><issue>12</issue><spage>1921</spage><epage>1930</epage><pages>1921-1930</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><coden>EPILAK</coden><abstract>Summary
Objective
Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients with treatment‐resistant seizures who were taking one to three concomitant antiepileptic drugs (AEDs). The VITOBA study (NCT01098162) evaluated the effectiveness and tolerability of adjunctive lacosamide added to one baseline AED in real‐world clinical practice.
Methods
We conducted a 6‐month observational study at 112 sites across Germany. Adult patients (≥16 years) with POS received lacosamide adjunctive to only one baseline AED. Seizure frequency reduction at the end of the observation period was compared with a 3‐month retrospective baseline period.
Results
Five hundred seventy‐one patients received lacosamide at least once (Safety Set [SS]); 520 provided evaluable seizure records (Full Analysis Set [FAS]); and 499 took in‐label dosages of lacosamide (up to 400 mg) and were evaluated for effectiveness (modified FAS). Median baseline seizure frequency was 2.0 per 28 days: 47.1% of patients (235/499, mFAS) took a concomitant sodium channel–blocking (SCB) AED; 38.1% (190/499) had only one lifetime AED; and 18.4% (92/499) were aged ≥65 years (mFAS). At the final visit, 72.5% (358/494) of patients showed a ≥50% reduction in seizure frequency from baseline, 63.8% (315/494) showed a ≥75% reduction, and 45.5% (225/494) were seizure‐free. Seizure freedom rates were higher in patients aged ≥65 years (56.7%) compared with patients aged <65 years (43.1%), in patients with ≤5 years epilepsy duration (52.5%) versus >5 years duration (41.0%), and when added to first monotherapy (60.5%) rather than as a later therapy option. Treatment‐emergent adverse events (TEAEs) were reported by 48.5% (277/571) of patients (SS), with a profile similar to that observed in pivotal trials; 466 of patients (81.6%, SS) continued lacosamide therapy after the trial.
Significance
These results suggest that lacosamide use, added to one concomitant AED, was effective at improving seizure control and was well tolerated in patients treated in routine clinical practice.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>26526971</pmid><doi>10.1111/epi.13224</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8666-1640</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2015-12, Vol.56 (12), p.1921-1930 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4737283 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acetamides - administration & dosage Acetamides - adverse effects Acetamides - therapeutic use Adjunctive Adolescent Adult Age Factors Aged Anticonvulsants - administration & dosage Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Antiepileptic drug Clinical medicine Drug Synergism Drug Therapy, Combination Epilepsies, Partial - drug therapy Epilepsy Female Full‐Length Original Research Humans Male Middle Aged Open‐label Prospective Studies Real‐world Safety Treatment Treatment Outcome Young Adult |
| title | A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A45%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20noninterventional%20study%20evaluating%20the%20effectiveness%20and%20safety%20of%20lacosamide%20added%20to%20monotherapy%20in%20patients%20with%20epilepsy%20with%20partial%E2%80%90onset%20seizures%20in%20daily%20clinical%20practice:%20The%20VITOBA%20study&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Runge,%20Uwe&rft.date=2015-12&rft.volume=56&rft.issue=12&rft.spage=1921&rft.epage=1930&rft.pages=1921-1930&rft.issn=0013-9580&rft.eissn=1528-1167&rft.coden=EPILAK&rft_id=info:doi/10.1111/epi.13224&rft_dat=%3Cproquest_pubme%3E1749613307%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1748599671&rft_id=info:pmid/26526971&rfr_iscdi=true |